Clinical Trials on Pancreatic Cancer Harboring NRG1 Fusion

Total 3256 results

Merus N.V.

Recruiting

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NSCLC Harboring NRG1 Fusion | Solid Tumours Harboring NRG1 Fusion | Pancreatic Cancer Harboring NRG1 Fusion | NRG1 Fusion

Spain, France, Israel, Belgium, Denmark, United States, Korea, Republic of, Japan, Germany, Netherlands, Austria, Canada, Italy, Norway, Singapore, Sweden, Taiwan, United Kingdom
Merus N.V.

Recruiting

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Metastatic Castration-resistant Prostate Cancer | NSCLC Harboring NRG1 Fusion

United States
Bayer

Approved for marketing

Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Tumors Harboring NTRK Fusion
Bayer

Completed

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Solid Tumors Harboring NTRK Fusion

United States
Bayer

Completed

Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body

Solid Tumors Harboring NTRK Fusion

Germany
Bayer

Completed

A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

Solid Tumors Harboring NTRK Fusion

United States
Bayer

Completed

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

Solid Tumors Harboring NTRK Fusion

United States
Jiangsu vcare pharmaceutical technology co., LTD

Completed

Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

China
Bayer

Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK)

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

United States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
Bayer

No longer available

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Solid Tumors Harboring NTRK Fusion
Bayer

Completed

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

Solid Tumors Harboring NTRK Fusion

United States, Belgium, Italy, Germany, Australia, Spain, Singapore, Denmark, France, Ireland
Bayer

Active, not recruiting

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT)

Solid Tumors Harboring NTRK Fusion

United States, China, Poland, Australia, Germany, Japan, Canada, Italy, Czechia, Spain, Turkey, United Kingdom, Sweden, Netherlands, France, Switzerland, Korea, Republic of, Denmark, Ireland, Israel, Ukraine
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Advanced Solid Tumors Harboring NTRK Fusion | Primary Central Nervous System Tumors Harboring NTRK Fusion

China
Bayer

Completed

An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Japan
Fore Biotherapeutics

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Cancer Harboring BRAF Alterations

United States, Germany, Spain, United Kingdom, France, Korea, Republic of, Italy, Sweden, Canada
Bayer

Recruiting

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Japan
Bayer

Active, not recruiting

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE)

Solid Tumors Harboring NTRK Fusion

United States, Korea, Republic of, China, Japan, India, France, Turkey, Portugal, Spain, Taiwan, Czechia, Sweden, Brazil, Denmark, Singapore, Argentina, Germany, Ireland
AZ-VUB
AstraZeneca; Kom Op Tegen Kanker

Recruiting

Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes (1-2018 BSMO)

Advanced Cancers Harbouring Mutations in HRG

Belgium
Yonsei University

Completed

Yield Rate for Procurement the Histologic Core With Endoscopic Ultrasound-guided Fine Needle Biopsy With 20-gauge Ultrasound Biopsy Needles for Solid Pancreatic Masses: Pilot Study

Pancreatic Cancer | Solid Pancreatic and Peripancreatic Lesion

Korea, Republic of
Rain Oncology Inc

Terminated

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN)

NSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB Fusion

United States, Canada, Hong Kong
Bayer

Completed

A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database (EPI VITRAKVI)

Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion | Infantile Fibrosarcoma

France
Centre Hospitalier Universitaire de Besancon

Not yet recruiting

Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions. (PANORAMA)

Benign Pancreatic Lesion

France
Gangnam Severance Hospital

Active, not recruiting

New Predictive Marker for Pancreatic Cancer Using CA19-9 and Fecal Elastase

Paancreatic Cancer

Korea, Republic of
Centre Leon Berard

Recruiting

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) (TRacKING)

Cancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditions

France, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
AZ-VUB

Unknown

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

Belgium
City of Hope Medical Center

Recruiting

Pancreatic Cancer Detection Consortium (PCDC)

Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditions

Korea, Republic of, United States, Japan
Sidney Kimmel Cancer Center at Thomas Jefferson...
Celgene

Withdrawn

Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy

Pancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study

Pancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic Carcinoma

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer

Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery

Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
National Cancer Institute (NCI)

Completed

Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery

Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
University of Wisconsin, Madison

Completed

Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer

Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
Fudan University

Unknown

Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

Stage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic Cancer

China
University of Utah
Novartis Pharmaceuticals

Recruiting

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer (THREAD)

Metastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer

United States
Shanghai Zhongshan Hospital
Fudan University

Not yet recruiting

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Pancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIB

China
Merus N.V.

Available

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Solid Tumor, Unspecified, Adult | Unknown Primary Tumors | NRG1 Fusion
National Health Research Institutes, Taiwan
National Taiwan University Hospital; National Cheng-Kung University Hospital

Completed

Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers (SOLAR)

Gastric Cancer in Situ | Pancreatic Cancers | Biliary Cancers

Taiwan
Memorial Sloan Kettering Cancer Center

Recruiting

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditions

United States
University of Oxford
National Institute for Health Research, United Kingdom; Imunon

Withdrawn

PanDox: Targeted Doxorubicin in Pancreatic Tumours (PanDox)

Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Pancreatic Cancer Non-resectable

United Kingdom
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Vaccinex...

Completed

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic... and other conditions

United States
Thomas Jefferson University

Recruiting

A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage 0 Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8 | Stage IA Pancreatic Cancer AJCC v8 | Stage IB Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Resectable Pancreatic Ductal Adenocarcinoma

United States
Istituto Scientifico Romagnolo per lo Studio e...

Completed

Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.

Unresectable Pancreatic Cancer | Locally Advanced Pancreatic Cancer | Nonmetastatic Pancreatic Cancer

Italy
City of Hope Medical Center
National Cancer Institute (NCI); National Institute of Nursing Research (NINR)

Completed

Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer

Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer

United States
National Cancer Institute (NCI)

Terminated

RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer

Adenocarcinoma of the Pancreas | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Resectable Pancreatic Carcinoma | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage IA Pancreatic Cancer AJCC v6 and v7 | Stage IB Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7 | Stage IIA Pancreatic Cancer AJCC v6 and v7 | Stage IIB Pancreatic Cancer AJCC v6 and v7

United States
Fundació Institut de Recerca de l'Hospital de la...
Spanish Clinical Research Network - SCReN

Completed

Antibiotic Prophylaxis for Endoscopic Ultrasound Guided Fine Needle Aspiration of Pancreatic Cystic Lesions

Pancreatic Cystic Lesion

Spain
OHSU Knight Cancer Institute
Oregon Health and Science University

Recruiting

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage 0 Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8

United States
National Cancer Institute (NCI)

Completed

Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

United States

Clinical Trials on Pancreatic Cancer Harboring NRG1 Fusion

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations